Recombinant protein carrying human papillomavirus epitopes inserted in an adenylate cyclase protein or fragment thereof therapeutic uses thereof

A therapeutic vaccine composition, comprising a recombinant Bordetella pertussis adenylate cyclase (CyaA) protein comprising:

• the HPV16-E7 fragment GQAEPDRAHYNIVTFCCKCDSTLRLCVQSTHVDIRTLEDLLMGTLGIVCPICSQKP (SEQ ID NO:
• 25) inserted at a first insertion site within the CyaA protein;
• and
• the HPV16-E7 fragment MHGDTPTLHEYMLDLQPETTDLYCYEQLN (SEQ ID NO:
• 26) inserted at a second insertion site within the CyaA protein;
• wherein the enzymatic activity of the recombinant CyaA protein has been genetically inactivated;
• and
• wherein administering the therapeutic vaccine composition to a mammalian subject infected with HPV prevents HPV-induced tumor growth in the subject.

A therapeutic vaccine composition, comprising a recombinant Bordetella pertussis adenylate cyclase (CyaA) protein comprising:

• amino acid residues 43 to 105 of HPV 18-E7 inserted at a first insertion site within the CyaA protein;
• and
• amino acid residues 1 to 31 of HPV 18-E7 inserted at a second insertion site within the CyaA protein;
• wherein the enzymatic activity of the recombinant CyaA protein has been genetically inactivated;
• and
• wherein administering the therapeutic vaccine composition to a mammalian subject infected with HPV prevents HPV-induced tumor growth in the subject.

A therapeutic vaccine composition, comprising:

• A) a first recombinant Bordetella pertussis adenylate cyclase (CyaA) protein comprising:
• the HPV16-E7 fragment GQAEPDRAHYNIVTFCCKCDSTLRLCVQSTHVDIRTLEDLLMGTLGIVCPICSQKP (SEQ ID NO:
• 25) inserted at a first insertion site within the CyaA protein;
• and
• the HPV16-E7 fragment MHGDTPTLHEYMLDLQPETTDLYCYEQLN (SEQ ID NO:
• 26) inserted at a second insertion site within the CyaA protein;
• wherein the enzymatic activity of the first recombinant CyaA protein has been genetically inactivated;
• and
• B) a second recombinant Bordetella pertussis adenylate cyclase (CyaA) protein comprising:
• amino acid residues 43 to 105 of HPV 18-E7 inserted at a first insertion site within the CyaA protein;
• and
• amino acid residues 1 to 31 of HPV 18-E7 inserted at a second insertion site within the CyaA protein;
• wherein the enzymatic activity of the second recombinant CyaA protein has been genetically inactivated;
• and
• wherein administering the therapeutic vaccine composition to a mammalian subject infected with HPV prevents HPV-induced tumor growth in the subject.